The Multiple Myeloma Channel is supported with funding from Sanofi (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | An NGS liquid biopsy approach vs standard bone marrow FISH for genomic characterization in myeloma
Efstathios Kastritis, MD, University of Athens School of Medicine, Athens, Greece, discusses a pilot study evaluating a peripheral blood NGS liquid biopsy approach for genomic profiling of monoclonal gammopathies and multiple myeloma. He highlights the correlation between liquid biopsy and bone marrow findings, the ability to detect additional genetic alterations, and the potential for blood-based testing to complement future disease assessment. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So our poster evaluates a new method that provides NGS evaluation in the peripheral blood for patients with monoclonal gammopathy, including patients with smoldering myeloma, MGUS, multiple myeloma newly diagnosed or relapsed. So in this study, we evaluate the feasibility of NGS, a targeted NGS panel, to provide comprehensive genetic evaluation of the patients. This is a pilot study and we still need more data...
So our poster evaluates a new method that provides NGS evaluation in the peripheral blood for patients with monoclonal gammopathy, including patients with smoldering myeloma, MGUS, multiple myeloma newly diagnosed or relapsed. So in this study, we evaluate the feasibility of NGS, a targeted NGS panel, to provide comprehensive genetic evaluation of the patients. This is a pilot study and we still need more data. However, it is very important that there is a significant correlation of the bone marrow findings and the peripheral blood findings. In addition, with the use of NGS, we were able to find additional genetic lesions that we were not, for example, in place to evaluate with the use of FISH in the bone marrow. I think that we are not very far from the implementation of peripheral blood-based methods to evaluate the genetics of the disease, which overcomes the issues of spatial heterogeneity. And I think maybe in the next five years, we will be in place to have approved methods to evaluate the patients.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
